N-PYRIDIN-3-YL-FORMAMIDE
- $29.8 - $3120
- Product name: N-PYRIDIN-3-YL-FORMAMIDE
- CAS: 22236-96-0
- MF: C6H6N2O
- MW: 122.12
- EINECS:
- MDL Number:MFCD00225523
- Synonyms:N-PYRIDIN-3-YL-FORMAMIDE;Formamide, N-3-pyridinyl-
5 prices
Selected condition:
Brand
- AccelPharmtech
- Crysdot
- Sigma-Aldrich
Package
- 25mg
- 1G
- 5G
- 25G
- ManufacturerAccelPharmtech
- Product numberD1176
- Product descriptionN-3-pyridinyl-Formamide 97.00%
- Packaging25G
- Price$3120
- Updated2021-12-16
- Buy
- ManufacturerAccelPharmtech
- Product numberD1176
- Product descriptionN-3-pyridinyl-Formamide 97.00%
- Packaging5G
- Price$1700
- Updated2021-12-16
- Buy
- ManufacturerAccelPharmtech
- Product numberD1176
- Product descriptionN-3-pyridinyl-Formamide 97.00%
- Packaging1G
- Price$1530
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11163514
- Product descriptionN-(Pyridin-3-yl)formamide 95+%
- Packaging1g
- Price$583
- Updated2021-12-16
- Buy
- ManufacturerSigma-Aldrich
- Product numberS243426
- Product descriptionN-PYRIDIN-3-YL-FORMAMIDE Aldrich
- Packaging25mg
- Price$29.8
- Updated2024-03-01
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AccelPharmtech | D1176 | N-3-pyridinyl-Formamide 97.00% | 25G | $3120 | 2021-12-16 | Buy |
AccelPharmtech | D1176 | N-3-pyridinyl-Formamide 97.00% | 5G | $1700 | 2021-12-16 | Buy |
AccelPharmtech | D1176 | N-3-pyridinyl-Formamide 97.00% | 1G | $1530 | 2021-12-16 | Buy |
Crysdot | CD11163514 | N-(Pyridin-3-yl)formamide 95+% | 1g | $583 | 2021-12-16 | Buy |
Sigma-Aldrich | S243426 | N-PYRIDIN-3-YL-FORMAMIDE Aldrich | 25mg | $29.8 | 2024-03-01 | Buy |
Properties
Melting point :93-94 °C
Boiling point :314.7±15.0 °C(Predicted)
Density :1.228±0.06 g/cm3(Predicted)
pka :14.07±0.70(Predicted)
Boiling point :314.7±15.0 °C(Predicted)
Density :1.228±0.06 g/cm3(Predicted)
pka :14.07±0.70(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|